BACKGROUND: The expression of myeloid cell leukemia 1 (Mcl-1) and p53 proteins was investigated for clinicopathological and prognostic significance in patients with gastric carcinoma. METHODS: Mcl-1 protein was immunohistochemically examined in 182 patients with gastric carcinoma. The overexpression of p53 was also analyzed in T3 gastric carcinomas. RESULTS: The expression of Mcl-1 was detected in 127 (69.8%) patients with gastric carcinoma. Mcl-1 was detected significantly more frequently in the undifferentiated type ( P < 0.05) and in the advanced stage of disease ( P < 0.05). The prognosis of patients with an Mcl-1-positive tumor was significantly worse than that of those with an Mcl-1-negative tumor ( P < 0.05). Multivariate analysis revealed that the expression of Mcl-1 was an independent prognostic factor, as were lymph node metastasis and tumor size. There was no significant relationship between the expression of Mcl-1 and p53. In patients with T3 gastric carcinoma who underwent curative surgery; however, Mcl-1(-)/p53 (-) tumor demonstrated the best postoperative survival rate, whereas Mcl-1(+)/p53(+) tumor had the worst. CONCLUSION: The expression of Mcl-1 is an indicator of tumor progression and postoperative recurrence in patients with gastric carcinoma. Combined analysis of Mcl-1 and p53 proteins may accurately predict the survival of patients with T3 gastric carcinoma.
BACKGROUND: The expression of myeloid cell leukemia 1 (Mcl-1) and p53 proteins was investigated for clinicopathological and prognostic significance in patients with gastric carcinoma. METHODS:Mcl-1 protein was immunohistochemically examined in 182 patients with gastric carcinoma. The overexpression of p53 was also analyzed in T3 gastric carcinomas. RESULTS: The expression of Mcl-1 was detected in 127 (69.8%) patients with gastric carcinoma. Mcl-1 was detected significantly more frequently in the undifferentiated type ( P < 0.05) and in the advanced stage of disease ( P < 0.05). The prognosis of patients with an Mcl-1-positive tumor was significantly worse than that of those with an Mcl-1-negative tumor ( P < 0.05). Multivariate analysis revealed that the expression of Mcl-1 was an independent prognostic factor, as were lymph node metastasis and tumor size. There was no significant relationship between the expression of Mcl-1 and p53. In patients with T3 gastric carcinoma who underwent curative surgery; however, Mcl-1(-)/p53 (-) tumor demonstrated the best postoperative survival rate, whereas Mcl-1(+)/p53(+) tumor had the worst. CONCLUSION: The expression of Mcl-1 is an indicator of tumor progression and postoperative recurrence in patients with gastric carcinoma. Combined analysis of Mcl-1 and p53 proteins may accurately predict the survival of patients with T3 gastric carcinoma.
Authors: Shanna K Nifoussi; Julie A Vrana; Aaron M Domina; Alfredo De Biasio; Jingang Gui; Mark A Gregory; Stephen R Hann; Ruth W Craig Journal: PLoS One Date: 2012-10-09 Impact factor: 3.240
Authors: Wenyi Luo; Teddy S Nagaria; Hongxia Sun; Junsheng Ma; Jamie L Lombardo; Roland Bassett; Austin C Cao; Dongfeng Tan Journal: Pathol Oncol Res Date: 2022-02-09 Impact factor: 3.201
Authors: D M Pritchard; D Berry; S M C Przemeck; F Campbell; S W Edwards; A Varro Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-08-21 Impact factor: 4.052